Skip to main content
Premium Trial:

Request an Annual Quote

Applied BioCode Raises $13.2M in Public Stock Offering

NEW YORK (GenomeWeb) – Applied BioCode announced today that it has secured $13.2 million through a public offering of its common stock.

In addition, the firm said it has also secured $8 million in total credit lines extended from an undisclosed FDIC-insured financial institution and a commercial lender.

Applied BioCode obtained US Food and Drug Administration clearance earlier this month for its MDx-3000 molecular diagnostics system along with a multiplex panel assay that tests for 17 gastrointestinal pathogens. The firm, which is a registered Cayman Islands corporation with facilities in the US and Taiwan, plans to use the new funds to commercialize the Gastrointestinal Pathogen Panel (GPP) and MDx-3000 in the US, noting in a statement that the system "will provide high-volume laboratories with an alternative to high-cost cartridge-based systems."

The GPP is the first test in a menu of multiplex infectious disease test panels that Applied BioCode will bring to market on the MDx-3000 system, the company added.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.